IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis by Moretti, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/138896
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
IL-37 Inhibits Inflammasome Activation and Disease
Severity in Murine Aspergillosis
Silvia Moretti1., Silvia Bozza1., Vasilis Oikonomou1, Giorgia Renga1, Andrea Casagrande1,2,
Rossana G. Iannitti1, Matteo Puccetti1, Cecilia Garlanda3, Soohyun Kim4, Suzhao Li4,
Frank L. van de Veerdonk5, Charles A. Dinarello4,5, Luigina Romani1*
1Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy, 2 Istituto Superiore di Sanita`, Roma, Italy, 3Humanitas Clinical and
Research Center, Rozzano, Milan, Italy, 4Department of Medicine, University of Colorado Denver, Aurora, Colorado, United States of America, 5Department of Medicine,
Radboud University Medical Centre, Nijmegen, The Netherlands
Abstract
Since IL-37 transgenic mice possesses broad anti-inflammatory properties, we assessed whether recombinant IL-37 affects
inflammation in a murine model of invasive pulmonary aspergillosis. Recombinant human IL-37 was injected
intraperitoneally into mice prior to infection and the effects on lung inflammation and inflammasome activation were
evaluated. IL-37 markedly reduced NLRP3-dependent neutrophil recruitment and steady state mRNA levels of IL-1b
production and mitigated lung inflammation and damage in a relevant clinical model, namely aspergillosis in mice with
cystic fibrosis. The anti-inflammatory activity of IL-37 requires the IL-1 family decoy receptor TIR-8/SIGIRR. Thus, by
preventing activation of the NLRP3 inflammasome and reducing IL-1b secretion, IL-37 functions as a broad spectrum
inhibitor of the innate response to infection-mediated inflammation, and could be considered to be therapeutic in reducing
the pulmonary damage due to non-resolving Aspergillus infection and disease.
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Introduction
IL-37 is a member of the IL-1 family of ligands discovered by
computational cloning and previously termed IL-1 family member
7 [1]. Five different splice variants of IL-37 have been described
[2,3]. The major splice variant is IL-37b [4] and, similar to most
members of the IL-1 family, lacks a clear signal peptide. The
precursor form is a ,30-kDa molecular mass protein that shares
critical amino acid residues with IL-18 [5]. In fact, IL-37 binds to
the IL-18 receptor [6] as well as the IL-18 binding protein [7]. The
first indication that IL-37 possessed anti-inflammatory properties
was observed with the combination of IL-37 plus IL-18 binding
protein [7]. Staining for IL-37 of human PBMC shows a granular
pattern in close proximity to the Golgi and endoplasmic reticulum,
a pattern, which suggests translocation via secretory vesicles [6,7].
IL-37 translocates to the nucleus and reduces LPS-induced
cytokines. The nuclear translocation of IL-37 requires caspase-1
activity as assessed by caspase-1 inhibitors [8] or by mutation of
the caspase-1 recognition aspartic acid in the IL-37 precursor [9].
IL-37 exerts anti-inflammatory effects by suppressing innate
immune responses through attenuating the production of inflam-
matory cytokines induced by TLR agonists, IL-1 and tumor
necrosis factor (TNF) [8,10].
IL-37 specific mRNA has been detected in a variety of normal
tissues and tumors in humans, where it is up-regulated by
inflammatory stimuli and cytokines [10–12], a finding suggesting
that IL-37 mediates a negative feedback mechanism to curb
excessive inflammation. Although a mouse homologue has not yet
been identified, IL-37b has been reported to act as an inhibitor of
inflammation in mice, a function achieved by inhibition of
dendritic cell activation on the cellular level and by interaction
with Smad3 and modulation of kinase checkpoints on the
molecular level [10]. Transgenic mice expressing human IL-37
on haematopoietic cells were protected from chemically-induced
colitis [13] and from local and systemic inflammation in ConA-
induced hepatitis and LPS challenge [14]. These results place IL-
37 within the portfolio of classical anti-inflammatory cytokines,
such as IL-10 and TGF-b [15].
Cytokines of the IL-1 family have important roles for antifungal
host defense in the lung [16] and IL-1 gene cluster polymorphisms
has been associated with susceptibility to aspergillosis in hemato-
logically suppressed patients [17]. IL-1a, IL-1b and IL-18 are
induced in alveolar macrophages, blood monocytes and neutro-
phils in response to Aspergillus in mice and humans. In turn, these
cytokines activate the release of other pro-inflammatory cytokines
such as TNF-a and IL-6, and induce antifungal Th17 responses
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[18–20]. In contrast to conidia, Aspergillus hyphae also induced
NLRP3 inflammasome assembly, caspase-1 activation and IL-1b
release from a human monocyte cell line [21]. However, given that
IL-1R1-deficient or caspase 1-deficient mice are resistant to lung
inflammation during aspergillosis [20,22] and that IL-1 signaling
could drive the differentiation of antifungal inflammatory Th17
cells [20,23], the proinflammatory properties of IL-1-induced
inflammation in aspergillosis is potentially dangerous for the host.
Therefore, in order to reduce inflammation in this model, we
assessed whether IL-37 would dampen inflammation in experi-
mental pulmonary inflammatory aspergillosis.
Results
IL-37 reduces inflammatory cell recruitment in mice with
aspergillosis
We first assessed the impact of the recombinant IL-37 precursor
(hereafter referred to as IL-37) on lung inflammation. The IL-37
precursor was administered intraperitoneally once either 96, 48 or
1 hour before intranasal infection with live A. fumigatus conidia.
Mice were monitored 1 and 3 days after the infection for BAL
morphometry, inflammatory cell recruitment and expression of
myeloperoxidase (Mpo) and chemokines. Although not affecting
the fungal burden in the lung (Figure 1A), IL-37 administered 1 h
before the infection at the dosage of 1000 and 100 ng/mouse (50
and 5 mg/kg, respectively) reduced BAL neutrophilia (Figure 1B),
neutrophil influx in the lung (Figure 1C), lung damage (Figure 1C,
insets) and lung expression of Mpo and CxCl2, an essential
mediator of host defense against A. fumigatus in mice [24] and
humans [25]. CxCl1 expression was instead unaffected (Fig-
ure 1D). These reductions were observed as early as 1 day after
the infection and appears to be long-lasting, being still present at 3
days post-infection, a time at which BAL neutrophilia (Figure 1B),
lung neutrophilic infiltration (Figure 1C) and Mpo and CxCl2
expression (Figure 1D) were drastically reduced. Accordingly, IL-
37 was effective when administered 96 or 48 hours before the
infection (Figure 1E and F). The effects was strictly dependent on
the route of administration, being lost upon local intranasal
injection (Figure 1E and F). Of interest, IL-37 was also effective in
dampening inflammation when administered after the infection
(Figure S1). Similar to Aspergillus, IL-37 also reduces neutrophil
infiltration in mice treated with LPS (Figure 1G), a finding
indicating that IL-37 inhibits TLR-dependent neutrophil recruit-
ment in lung infections as reported previously [10].
IL-37 impairs inflammasome activation in mice with
aspergillosis
As uncontrolled IL-1b promotes detrimental neutrophil-depen-
dent inflammation during aspergillosis [20], we examined whether
IL-37 pretreatment affects the level of IL-1b production and
inflammasome activation. As shown in Figure 2 by immunohis-
tochemistry (Figure 2A) and RT-PCR (Figure 2B), lung NLRP3
expression increased after the infection in both epithelial and in
the recruited inflammatory cell compartment. IL-37, at 1000 and
100 ng/mouse, greatly reduced Nlrp3 steady state mRNA levels
in the lungs. IL-1b was also decreased by IL-37, as revealed by
RT-PCR (Figure 2B), ELISA (Figure 2C) and pro-IL-1b and
caspase-1 cleavage by immunoblotting (Figure 2D). IL-37 did not
inhibit the expression of Il1a (Figure 2B), did not change that of
Il1ra (Figure 2B), known to inhibit inflammasome activation [26],
and only partially reduced the expression Tnfa and Il6
(Figure 2B). IL-37 also reduced the expression of Il17a and Ifng
(Figure 2E) and greatly increased that of Il10 (Figure 2C and E).
However, the induction of IL-10 did not apparently account for
the anti-inflammatory activity of IL-37, as IL-37 still retained its
effects in IL-10-deficient mice (Figure S2). This finding is in line
with what described in experimental colitis in which an antibody
to the IL-10 receptor did not affect the anti-inflammatory
properties of transgenic mice expressing human IL-37 [13]. Thus,
these data indicate that IL-37 may limit the recruitment of
inflammatory neutrophils and damage in infected lungs by
dampening NLRP3 inflammasome activation. To directly prove
this, we assessed NLRP3-deficient mice for susceptibility to
aspergillosis and the effects of IL-37 administration. The results
showed that neutrophil recruitment in the BAL (Figure 3A) and
lungs (Figure 3B), Mpo and Cxcl2 expression (Figure 3C) and IL-
1b production (Figure 3D) were lower in NLRP3-deficient than
wild-type mice and were not modified by IL-37 treatment. These
data suggest that one mechanism by which IL-37 exerts its anti-
inflammatory effects in lung aspergillosis is by inhibition of
NLRP3 inflammasome activity.
IL-37 dampens inflammatory pathways in phagocytic
cells
In order to identify which cell type is responsive to IL-37, we
assessed the ability of IL-37 to affect the expression of Il1b in
purified alveolar macrophages, lung epithelial cells and peripheral
neutrophils from naı¨ve mice in response to Aspergillus conidia.
We did not observe that IL-37 decreased phagocytic capacity and
fungicidal activity of phagocytes in vitro (Figure 4A), nevertheless
recombinant IL-37 inhibited the expression of Il1b in response to
conidia, in both macrophages and neutrophils (Figure 4B).
Epithelial cells poorly responded to conidia stimulation, with
and without IL-37 (Figure 4B). Of interest, IL-37 induced the
expression of the inducible nitric oxide (Nos2), known to suppress
inflammasome activation [27] and Th17 development [28]. IL-37
inhibits MAP kinase p38a in the human monocytic THP1 cell line
[10]; therefore, we measured the phosphorylation of 19 kinases in
the murine leukemic monocyte macrophage cell line RAW 264.7
pretreated with IL-37 and exposed to Aspergillus conidia, known
Author Summary
IL-37, firstly identified by in silico research in the year 2000,
is a member of the IL-1 family. The biological properties of
IL-37 are mainly those of down-regulating inflammation in
models of septic shock, chemical colitis, cardiac ischemia
and contact dermatitis. Whether and how IL-37 down-
regulates the inflammation of infection, and its conse-
quences, is not known. We observed that IL-37 limits
inflammation and disease severity in murine invasive
aspergillosis, an infection model in which cytokines of
the IL-1 family have important roles. However, given that
IL-1R1-deficient or caspase 1-deficient mice are resistant to
lung inflammation during infection and that IL-1 signaling
could drive the differentiation of antifungal inflammatory
Th17 cells, the pro-inflammatory properties of IL 1-induced
inflammation in aspergillosis is potentially dangerous for
the host. IL-37 markedly reduced NLRP3-dependent
neutrophil recruitment and steady state mRNA levels of
IL-1b production and mitigated lung inflammation and
damage in a relevant clinical model, namely aspergillosis in
mice with cystic fibrosis. The anti-inflammatory activity of
IL-37 requires the IL-1 receptor family decoy TIR-8/SIGIRR.
Thus, IL-37 functions as a broad spectrum inhibitor of
infection-mediated inflammation, and could be considered
to be therapeutic in reducing the pulmonary damage due
to non-resolving Aspergillus infection and disease.
IL-37 Inhibits Inflammasome Activation
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to trigger the phosphorylation of p38 [29]. IL-37 greatly reduced
p38a phosphorylation and, to a lesser extent, ERK1/2 phosphor-
ylation in response to conidia (Figure 4C). These results indicate
that IL-37 affects signal transduction pathways in response to
conidia, likely impacting Il1b and Nos2 gene expression.
IL-37 fails to inhibit inflammasome activation in TIR-8/
SIGIRR-deficient mice
We reported that TIR-8/SIGIRR is required for host resistance
to fungal infections by reducing IL-1b–dependent activation of
inflammatory Th17 responses [20]. In the present study, we
assessed whether the inhibitory activity of recombinant IL-37
would require TIR-8/SIGIRR. To this purpose, we evaluated the
impact of IL-37 on inflammasome activation and inflammation in
Tir82/2 mice with aspergillosis. Consistent with previous findings
[20], increased BAL neutrophilia (Figure 5A) and lung inflamma-
tion (Figure 5B) were observed in Tir82/2 mice along with an
heightened expression of NLRP3 (Figure 5B inset). Consistently,
Mpo, CxCl2 (Figure 5C), Il1b and Il17a (Figure 5D) expression as
well as the cleavage of the IL-1b precursor (Figure 5E) were all up-
regulated in these mice. Treatment with 1000 ng/mouse of IL-37
one h before the infection neither limited inflammatory cell
recruitment nor inhibited the heightened NALP3 expression
activation in these mice (Figure 5B–E). IL-37 also failed to restore
Il10 expression in these mice (Figure 5D). These data support the
concept that TIR-8/SIGIRR signaling is required for the anti-
inflammatory effects of IL-37.
IL-37 limits inflammation in fungal allergy and mice with
cystic fibrosis
To evaluate the potential for IL-37 to limit inflammation also in
Aspergillus allergy, we resorted to a murine model of allergic
bronchopulmonary aspergillosis (ABPA) in which both the Th2
and Th17 cell responses contribute to the inflammatory response
[30]. Mice were sensitized to Aspergillus antigens and concom-
itantly treated with 1000 ng/mouse of IL-37. We found that IL-37
reduced mucin production (Figure 6A) and peribronchial fibrosis
due to collagen deposition as shown by Masson’s trichrome
staining (Figure 6A) and hydroxyprolin content (Figure 6B). In
addition, IL-37 markedly reduced the expression of the mucin
Muc-5/5ac gene, a known marker of globlet cells metaplasia in
murine airways [9]. In addition, IL-37 greatly decreased
inflammatory cell recruitment and Th2/Th17cell activation
(Figure 6D), a finding indicating that IL-37 has the potential to
impact on the adaptive immune response. To evaluate the anti-
allergic activity of IL-37 in a clinically relevant model, we resorted
to Cftr tm1Unc (Cftr2/2) mice that are considered to mimic, to
some extent, the airway inflammation and infection of human
cystic fibrosis (CF) [31,32]. We have already shown that Cftr2/2
mice are highly susceptible to Aspergillus infection and allergy,
due to an heightened inflammatory Th17/Th2 response [33].
Cftr2/2 mice were pretreated with 1000 ng/mouse IL-37 one h
before the infection and parameters of infection and inflammation
were evaluated one day after the infection. We observed that IL-37
pretreatment, while not affecting the fungal burden (Figure 6E),
decreased the numbers of neutrophils in BAL (Figure 6F) and
lungs (Figure 6G) associated with lower expression of Mpo and
Cxcl2 (Figure 6H). IL-37 also decreased the expression Il1b,
Il17a, Il4 and increased that of Il10 and Ifng (Figure 6I). These
data point to IL-37 as a potent regulator of inflammation during
respiratory fungal infection and allergy.
Discussion
This study is the first to show the activation of the NLRP3
inflammasome in vivo during A. fumigatus infection and its
inhibition by recombinant IL-37 precursor. Members of the
inflammasome family are key players in host defense against
Candida albicans [34–36] and control fungal opportunism and
pathogenicity [37]. Activation of NLRP3 has also been shown in
response to A. fumigatus in vitro [21], but a functional role in
infection has not been demonstrated. Here, we observed that the
activation of the NLRP3 inflammasome is associated with
increased secretion of IL-1b and chemokines that mediate
neutrophil recruitment into the lung. Although neutrophils serve
potent antifungal effector function [38], in conditions of non-
resolving inflammatory responses, neutrophils drive detrimental
inflammation. Indeed, in such settings, mice deficient in IL-1R1
are protected [22,38] and mice with hyper-functioning of IL-1b
signaling have detrimental inflammatory responses [20]. There-
fore, inflammasome activation and IL-1b secretion can drive
pathological sequelae during Aspergillus infection. Although
overexpression of IL-37 reduces IL-1beta secretion [10], the
capacity of IL-37 to inhibit NLRP3 activation and IL-1b-mediated
chemokine production described here impacts directly on inflam-
matory cell recruitment in the lung and on the Th balance. IL-37
decreased tissue damage during infection, a finding suggesting that
regulation of inflammatory cell recruitment is essential to maintain
normal tissue function. The ability to limit inflammatory cell
recruitment was also observed in response to LPS, a finding
consistent with the ability of IL-37 to reduce LPS-induced pro-
inflammatory cytokine expression [10] and further pointing to a
protective effect for IL-37 in respiratory infections.
The immunomodulatory action of IL-37 appears to occur at the
level of myeloid cells, likely bone marrow-recruited macrophages
and neutrophils, whose transcriptional program in response to
conidia was indeed modified in the presence of recombinant IL-
37. IL-37 increased Nos2 gene expression, a finding that may
suggest an impairment of the fungicidal activity of effector
phagocytes by IL-37. However, we did not observe decreased
phagocytic capacity or impaired fungicidal activity of phagocytes
in vitro in the presence of IL-37. IL-37 increased the expression of
b-defensins and cathelicidin, which may play a role in antifungal
Figure 1. IL-37 reduces inflammatory cell recruitment in mice with inflammatory aspergillosis. C57BL/6 mice were infected intranasally
(in) with A. fumigatus and pretreated one time with different doses IL-37 administered intraperitoneally (ip) at different times before the infection.
Mice were assessed for: (A) fungal growth (Log10 CFU, mean6SD) in the lungs at 1 and 3 days post-infection (dpi); (B) BAL fluid morphometry
[number of total (T) cells and polymorphonuclear neutrophils (P) upon May Grunwald Giemsa staining. Values represent the mean6SD of three mice
per group and are representative of 3 independent experiments]; (C) lung histology (periodic acid-Schiff and, in the inset, TUNEL staining). Red
arrows indicate PMN and white arrows indicate increased deposition of DNA on lung parenchyma (in TUNEL-stained sections). Scale bars, 25 mm; (D)
myeloperoxidase (Mpo), Cxcl1 and Cxcl2 mRNA expression by RT-PCR on total lung cells; (E) lung histology (periodic acid-Schiff staining, scale bars,
25 mm) and (F) Mpo, Cxcl1 and Cxcl2 mRNA expression (RT-PCR on total lung cells) in mice pretreated with IL-37 given ip or in, at different hours
before the infection. (G) Numbers of CD11b/Gr1–positive cells were assessed by flow cytometry of total lung cells from LPS-treated mice. Data are
representative (histology) or pooled from three experiments. *P,0.05,**P,0.01, treated vs untreated (None) mice. Naı¨ve, uninfected and untreated
mice.
doi:10.1371/journal.ppat.1004462.g001
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host defense [39], but the contribution of these peptides to the
control of fungal growth by IL-37 is presently unknown.
Regardless of the specific downstream signaling pathways
mediating the effects of IL-37, TIR8/SIGIRR is required. The
Toll IL-1 Receptor (TIR) domain of SIGIRR has two mutations
which likely act as decoys for MyD88 activation for IL-1 as well as
TLR signaling. TIR-8 inhibits signaling receptor complexes of IL-
1 family members associated with Th1 (IL-18), Th2 (IL-33) and
Figure 2. IL-37 impairs inflammasome activation in mice with aspergillosis. C57BL/6 mice were infected intranasally with A. fumigatus and
treated intraperitoneally with recombinant IL-37 precursor, at the indicated doses, 96, 48 and 1 hour before the infection. (A) NLRP3 expression in the
lung by immunofluorescence staining with anti-CIAS1/Nlrp3 antibody. In the insets, positive staining of epithelial cells. Nuclei were counterstained
with DAPI. Scale bars, 100 mm. (B, E) Gene expression on total lung cells by RT-PCR. (C) Cytokine production (ELISA) on lung homogenates. (D)
Immunoblot analysis on whole lung lysates of IL-1b and Caspase 1 using rabbit specific antibodies and rabbit anti-actin. Goat anti-rabbit IgG-HRP
were used as secondary antibody. Corresponding pixel density ratio was normalized against actin. Assays were done a day after the infection. Data
are representative (immunoblotting) or pooled from three experiments. *P,0.05, **P,0.01, treated vs untreated (None) mice. Naı¨ve, uninfected and
untreated mice.
doi:10.1371/journal.ppat.1004462.g002
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Th17 (IL-1) and induces tolerogenic responses [40]. Thus, TIR-8/
SIGIRR emerges as a non-redundant receptor for dampening
inflammation and tissue damage in respiratory infections [20,40].
In fungal infections, signaling through TIR-8/SIGIRR was
required for the prevention of lethal inflammatory pathology
associated with disregulated IL-1-dependent Th17 responses
[20,41].
Little is known about the interaction between TIR-8/SIGIRR
and other members of the superfamily [42]. IL-37b may recruit
TIR8/SIGIRR to activate the anti-inflammatory pathway [11].
Our study clearly shows that TIR-8/SIGIRR is involved in the
anti-inflammatory activity of IL-37, but the molecular mechanisms
of this interaction remains to be fully elucidated.
In the era in which damage control more than pathogen control
has been suggested to provide new approaches for the treatment of
infections and other diseases [43], our study seems to qualify IL-37
as an endogenous mediator of tissue tolerance during acute
Aspergillus infection, likely including that occurring in the setting
of neutrophil recovery. Moreover, the ability of IL-37 to also affect
the development of adaptive immunity may suggest that recom-
binant IL-37 could be of benefit in conditions of non-resolving
detrimental inflammation during acute Aspergillus infection but
also fungal allergy.
Materials and Methods
Ethics statement
Murine experiments were performed according to the Italian
Approved Animal Welfare Assurance A-3143-01 and Legislative
decree protocol number 245/2011-B regarding the animal license
obtained by the Italian Ministry of Health lasting for three years
(2011–2014). Infections were performed under avertin anesthesia
and all efforts were made to minimize suffering. The experimental
protocol was designed in conformity with the recommendations of
the European Economic Community (86/609/CEE) for the care
and the use of laboratory animals, was in agreement with the
Good Laboratory Practices and was approved by the animal care
Committee of the University of Perugia (Perugia, Italy).
Mice
Six to eight-week C57BL/6 (wild-type) female mice were
purchased from Charles River (Calco, Italy). Genetically engi-
neered homozygous Cftr2/2 mice [44] were bred at the Cystic
Fibrosis core animal facility at San Raffaele Hospital, Milan, Italy.
Tir82/2 mice were raised on a 129/Sv and C57BL/6J mixed
genetic background. Il102/2 mice were bred at the Animal
Facility of the University of Perugia, Perugia, Italy. Nlrp32/2 mice
were obtained from Francis Derouet, Universite´ de Lausanne,
Switzerland.
Recombinant human IL-37
Full-length human IL-37 precursor with amino acids 1–218 (IL-
37B isoform), was inserted in pCACTUS with a chicken beta actin
promoter and N-terminal 6-histidines. After expression in E. coli,
the recombinant molecule was purified on Talon followed by
FPLC size exclusion. The peak isolated from the FPLC was
applied to a C6 HPLC column and the IL-37 peak eluted in
acetonitrile, isolated and lyophilized. The lyophilized IL-37 was
reconstituted in PBS. On silver PAGE, recombinant IL-37 appears
as a single band with a MW of 34 kDa.
Fungal infection, allergy and treatment
Viable conidia from the A. fumigatus Af293 strain were
obtained as described [30]. Mice were anesthetized in a plastic
cage by inhalation of 3% isoflurane (Forane Abbot) in oxygen
before intranasal instillation of 26107 resting conidia/20 ml saline.
Recombinant human IL-37 was given intraperitoneally at different
times (96, 48 and 1 hour) and at different concentrations (1000,
100, 10 and 1 ng/mouse) before the infection. Controls received
the diluent alone. Mice were monitored for cell recruitment in the
bronchoalveolar lavage fluid (BAL), histopathological analysis and
Figure 3. NLRP3-deficient mice exhibit reduced neutrophil
recruitment and IL-1b production in pulmonary aspergillosis.
C57BL/6 and Nlrp32/2 mice were infected intranasally with A. fumigatus
and treated with 1000 ng/mouse recombinant IL-37 precursor admin-
istered intraperitoneally 1 hour before the infection. (A) BAL fluid
morphometry [number of total (T) cells and polymorphonuclear
neutrophils (P). Values represent the mean6SD of three mice per
group and are representative of 3 independent experiments]. (B) Lung
histology (periodic acid-Schiff staining) and cell recruitment (insets).
Scale bars, 100 mm and 25 mm, respectively. Arrows indicate neutro-
phils. (C) Mpo and Cxcl2 mRNA expression by RT-PCR on total lung cells.
(D) IL-1b production (ELISA on lung homogenates). Assays were done 3
days after the infection. Data are representative (histology) or pooled
from three experiments. *P,0.05, Nlrp32/2 vs C57BL/6 mice and
treated vs untreated (None) mice. Naı¨ve, uninfected and untreated
mice.
doi:10.1371/journal.ppat.1004462.g003
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Figure 4. IL-37 dampens inflammasome activation in phagocytic cells. Alveolar macrophages and epithelial cells from naive mice and
peripheral neutrophils were pre-exposed to recombinant IL-37 precursor for 8 hours before stimulation with live Aspergillus conidia for 2 hours. (A)
Percent of phagocytosis and conidiocidal activity. (B) Il1b and Nos2 mRNA expression by RT-PCR on total lung cells. Ct, control cells. None, Aspergillus-
pulsed, untreated cells. (C) Activation of distinct intracellular kinases in RAW cells, using Proteome Profiler Array, pre-exposed to 100 ng/ml IL-37 for
8 hours before stimulation with live Aspergillus conidia for 30 min. Data are representative (Proteome Profiler Array) or pooled from two experiments.
*P,0.05,**P,0.01, ***P,0.001, IL-37-stimulated vs unstimulated cells.
doi:10.1371/journal.ppat.1004462.g004
IL-37 Inhibits Inflammasome Activation
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chemokine or cytokine expression and production. For allergy,
mice received an i.p. and s.c. injection of 100 mg of A. fumigatus
culture filtrate extract (CCFA) dissolved in incomplete Freund’s
adjuvant (Sigma-Aldrich) followed by two consecutive intranasal
injections (a week apart) of 20 mg CCFA. A week after the last
intranasal challenge, mice received 107 Aspergillus resting conidia
and evaluated a week later [30]. IL-37 (1000 ng) was administered
in concomitance with CCFA sensitization and Aspergillus
inoculation. Ultrapure LPS from Salmonella minnesota Re 595
(Sigma-Aldrich) was given intranasally at the concentration of
10 mg/mouse. For histology, paraffin-embedded tissues were
stained with Periodic acid-Schiff (PAS) and with Masson’s
trichrome staining to investigate the collagen deposition. Photo-
graphs were taken using a high- resolution Olympus DP71
microscope.
Collection of BAL
Lungs were filled thoroughly with 1.0 ml aliquots of pyrogen-
free saline through a 22-gauge bead-tipped feeding needle
introduced into the trachea. BAL fluid was collected in a plastic
tube on ice and centrifuged at 4006 g at 4uC for 5 min. For
differential BAL fluid cell counts, cytospin preparations were
stained with May-Gru¨nwald Giemsa reagents (Sigma-Aldrich). At
least 10 fields (200 cells/field) were counted, and the percent of
polymorphonuclear (PMN) and mononuclear (MNC) cells was
calculated [45]. Photographs were made using a high-resolution
Olympus DP71 microscope.
Terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate nick-end labeling (TUNEL) of
lung sections
The lungs were fixed in 4% buffered paraformaldehyde,
pH 7.3, for 36 h and embedded in paraffin. Sections were de-
paraffinized, re-hydrated and treated with 0.1 M citrate buffer,
pH 6.0, for 20 min in a water bath, washed and blocked in 0.1 M
Tris/HCl buffer, pH 7.5, supplemented with 3% bovine serum
albumin and 20% FCS. The slides were then incubated with
fluorescein-coupled dUTP and TUNEL enzyme (Roche Diagnos-
tics) in the presence of terminal deoxynucleotidyl transferase. The
samples were then washed with PBS, incubated for 10 min at
70uC to remove unspecific binding. The sections were mounted
and analyzed by fluorescent microscopy using a 406 objective.
Immunofluorescence
The lung was removed and fixed in 10% phosphate-buffered
formalin, embedded in paraffin and sectioned at 5 mm. Sections
were then rehydrated and after antigen retrieval in citrate buffer
(10 mM, pH 6), sections were blocked with 5% BSA in PBS and
stained with goat-anti-CIAS1/Nlrp3 antibody overnight at 4uC
Figure 5. IL-37 fails to inhibit inflammasome activation in Tir82/2mice. Tir82/2 mice were infected intranasally with A. fumigatus and treated
intraperitoneally with recombinant IL-37 precursor, at the dose of 1000 ng/mouse, 1 hour before the infection. (A) BAL fluid morphometry [number
of total (T) cells and polymorphonuclear neutrophils (P). Values represent the mean6SD of three mice per group and are representative of 3
independent experiments]. (B) Lung histology (PAS-stained sections). Scale bars, 25 mm. In the insets, NLRP3 expression by immunofluorescence
staining of epithelial cells. Images were acquired using a fluorescence microscope with a 406objective. Nuclei were counterstained with DAPI. (C)
Mpo and Cxcl2 mRNA expression and (D) cytokine gene expression (RT-PCR) on total lung cells. (E) Immunoblot with rabbit polyclonal IL-1b-specific
antibody on whole lung lysates. Assays were done 3 days post-infection. Data are representative (histology) or pooled from two experiments. None,
untreated mice. Naı¨ve, uninfected and untreated mice.
doi:10.1371/journal.ppat.1004462.g005
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followed by donkey anti-goat IgG H&L (DyLight 488) secondary
antibody (both from Abcam). Images were acquired using a
fluorescence microscope (BX51 Olympus) with a 206 objective
and the analySIS image processing software (Olympus). 49-6-
Diamino-2-phenylindole (DAPI, Molecular Probes, Invitrogen)
was used to counterstain tissues and to detect nuclei.
Cell preparation, phagocytosis, conidiocidal activity and
culture
Alveolar macrophages were isolated from total lung cells after 2-
hour plastic adherence at 37uC. Murine CD11b+ Gr-1+ neutro-
phils were positively selected with magnetic beads (Miltenyi
Biotech) [46] from the peritoneal cavity of uninfected wild-type
mice 8 h after the intraperitoneal injection of 1 ml endotoxin-free
10% thioglycollate solution. Endotoxin was depleted from all
solutions with Detoxi-gel (Pierce). On fluorescence-activated cell
sorting (FACS) analysis, Gr-1+ neutrophils were .98% pure and
stained positive for the CD11b myeloid marker. Lung epithelial
cells were isolated as described [39]. Cells were pre-exposed to IL-
37 for 8 hours before stimulation with live Aspergillus conidia for
2 hours for the assessment of phagocytosis, conidiocidal activity
and cytokine gene expression.
Whole proteomic RAW analysis
RAW 264.7 cells (ATCC) were exposed to 100 ng/ml IL-37
precursor for 8 hours before stimulation with live Aspergillus
Figure 6. IL-37 restrains inflammation in fungal allergy and Cftr2/2mice. (A) Lung histology (PAS- and Masson’s trichrome-stained sections,
scale bars 100 and 25 (insets) mm); (B) hydroxyproline content (mg/lung); (C) expression of mucins (RT-PCR on total lung cells); (D) expression of
cytokines and Th transcription factors in total lung cells from mice with ABPA and treated with IL-37. None, untreated mice. Naı¨ve, uninfected and
untreated mice. (E) Fungal growth (Log10 CFU, mean6SD) in the lungs of Cftr
2/2 mice infected intranasally with A. fumigatus and treated
intraperitoneally with IL-37, at the dose of 1000 ng/mouse, 1 hour before the infection. (F) BAL fluid morphometry [number of total (T) cells and
polymorphonuclear neutrophils (P) upon May Grunwald Giemsa staining]. (G) Lung histology (periodic acid-Schiff staining) and cell recruitment
(insets). Scale bars, 100 mm and 25 mm in the insets; (H) Mpo and Cxcl2 mRNA expression and (I) cytokine gene expression on total lung cells by RT-
PCR, 3 days after the infection. Data are pooled from two experiments. *P,0.05, **P,0.01, treated vs untreated (None) mice. Naı¨ve, uninfected and
untreated mice.
doi:10.1371/journal.ppat.1004462.g006
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conidia at a cell/fungi ratio of 1:1, for 30 minutes. The relative
phosphorylation of 26 Phospho-Mitogen-activated Protein Kinase
(MAPK) was performed using the Proteome ProfilerArray (R&D
Systems). Kinases were captured by 26 different antibodies spotted
in duplicate on a nitrocellulose membrane. Levels of phosphor-
ylated protein were then assessed using phospho-specific antibod-
ies and chemiluminescent detection.
Western blot analysis
An equal amount of whole lung tissue were lysed in 26Laemli
buffer and separated in 14% Tris/glicine SDS gel, transferred to a
nitrocellulose membrane, probed with rabbit anti-mouse IL-1b
(Biolegend) or rabbit anti-caspase-1-p10 (Santa Cruz). Goat anti-
rabbit IgG-HRP (Sigma-Aldrich) was used as secondary antibod-
ies. Normalization was performed on rabbit anti-actin antibody
(Santa Cruz) and quantification was obtained by densitometric
image analysis using Image Lab 3.1.1 software (Bio-Rad) as
previously described [47].
Flow cytometry analysis
All staining reactions were performed at 4uC on cells first
exposed to Fc receptor mAb (2.4G2) in order to reduce nonspecific
binding. Anti CD11b (M1/70) and anti-CD11c (N418) were
purchased from BD Biosciences-Pharmingen. Cells were analyzed
with a BD LSRFortessa flow cytometer (BD) equipped with BD
FACSDiva 7.0 software.
ELISA and real-time PCR
The levels of cytokines in lung homogenates were determined
by mouse ELISAs (R&D Systems). The detection limits of the
ELISAs were less than 3 pg/ml for IL-10 and 5 pg/ml for IL-1b,
respectively. Real-time RT-PCR was performed using the
Stratagene Mx3000P QPCR System and SYBR Green chemistry
(Stratagene). Cells were lysed and total RNA was reverse
transcribed with cDNA Synthesis Kit (BioRad), according to the
manufacturer’s instructions. The PCR primers were as listed in
Table 1. Amplification efficiencies were validated and normalized
against GAPDH. The thermal profile for SYBR Green real-time
PCR was at 95uC for 3 min, followed by 40 cycles of denaturation
for 30 s at 95uC and an annealing/extension step of 30 sec at
60uC. Each data point was examined for integrity by analysis of
the amplification plot. The mRNA-normalized data were
expressed as relative gene mRNA in treated compared to
untreated experimental groups or cells.
Hydroxyproline assay
The total collagen content of the lung tissue was measured
spectrophotometrically by absorbance at 560 nm to quantify the
lung hydroxyproline content 7 days after infection. Briefly, the
minced lung lobes were homogenized in dH2O, using 100 ml H2O
for every 10 mg of tissue. To a 100 ml of sample homogenates, add
100 ml concentrated 12 N HCl in a pressure-tight, teflon capped
vial and hydrolyze at 120uC for 3 hours. After reaction with
Chloramine T reagent (incubate at room temperature for 5 min)
and DMAB reagent (incubate for 90 min at 60uC), the absorbance
was measured at 560 nm. The results were expressed as mg
hydroxyproline per mg of wet lung weight using a standard curve
(0,1 mg/ml) (BioVision).
Statistical analysis
Data are expressed as mean 6 SD. Horizontal bars indicate the
means. For multiple comparisons, p values were calculated by a
one-way ANOVA (Bonferroni’s post hoc test). For single
comparison, p values were calculated by a twotailed Student’s t
test. The data reported are either from one representative
experiment (histology, TUNEL and western blotting) or pooled
otherwise. The in vivo groups consisted of 4–6 mice/group. Data
Table 1. Real-time murine PCR primers used in this study.
Gene name Primer sequence
Mpo Forward, 59-TTACACCCCAGGCATAAAAA-39
Reverse, 59-TTCCATACAGCTCAGCACAA-39
Cxcl1 Forward, 59-CCGCTCGCTTCTCTGTGC-39
Reverse, 59-CTCTGGATGTTCTTGAGGTGAATC-39
Cxcl2 Forward, 59-CCAACCACCAGGCTACAG-39
Reverse, 59-CTTCAGGGTCAAGGCAAAC-39
Gata3 Forward, 59-TCTGGAGGAGGAACGCTAATG-39
Reverse, 59-GGCTGGAGTGGCTGAAGG-39
Rorc Forward, 59-ACAACAGCAGCAAGTGATGG-39
Reverse, 59-CCTGGATTTATCCCTGCTGA-39
Tnfa Forward, 59-CGAGTGACAAGCCTGTAGCC-39
Reverse, 59-AAGAGAACCTGGGAGTAGACAAG-39
IL6 Forward, 59-CCGGAGAGGAGACTTCACAG-39
Reverse, 59-TCCACGATTTCCCAGAGAAC-39
Ifng Forward, 59-ACTGGCAAAAGGATGGTGAC-39
Reverse, 59-TGAGCTCATTGAATGCTTGG-39
Il17a Forward, 59-GACTACCTCAACCGTTCCAC-39
Reverse, 59-CCTCCGCATTGACACAGC-39
Il4 Forward, 59-CGGCATTTTGAACGAGGTCACAGG-39
Reverse, 59-AGCACCTTGGAAGCCCTACAGACG-39
Il10 Forward, 59-CCCTTTGCTATGGTGTCCTT-39
Reverse, 59-TGGTTTCTCTTCCCAAGACC-39
Nalp3 Forward, 59-ATGCTGCTTCGACATCTCCT-39
Reverse, 59-GTTTCTGGAGGTTGCAGAGC-39
Il1b Forward, 59-TGACGGACCCCAAAAGATGAAGG-39
Reverse, 59-CCACGGGAAAGACACAGGTAGC-39
Il1a Forward, 59-CTGCAGTCCATAACCCAT-39
Reverse, 59-TGACAAACTTCTGCCTGACG-39
Il1ra Forward, 59-TTGTGCCAAGTCTGGAGATG-39
Reverse, 59-CAGCTGACTCAAAGCTGGTG-39
p47 Forward, 59- TAGAGACTCCTCCCATGCCT -39
Reverse, 59- CACTGCCTCCTCTCATGCTA -39
p67 Forward, 59- CTATCTGGGCAAGGCTACGGTT -39
Reverse, 59- CACAAAGCCAAACAATACGCG -39
gp91 Forward, 59-AAAGGAGTGCCCAGTACCAAAGT-39
Reverse, 59-TACAGGAACATGGGACCCACTAT-39
Nos2 Forward, 59-GGACACTGCCGCCAACATCTAC-39
Reverse, 59-CACCCAAAGTGCTTCAGTCA-39
Muc1 Forward, 59-TGAGCCAGGACTTCTGGTAG-39
Reverse, 59-CCTTCTGAGAGCCACCACTA-39
Muc5ac Forward, 59-CTGGACCTGGAGGTTGTATG-39
Reverse, 59-CAGTAGTGAGGGTTGGATGG-39
Muc13 Forward, 59-ACATGGTGAAGGGTCAAGAA-39
Reverse, 59-AGATGAACTACCCACGGTCA-39
doi:10.1371/journal.ppat.1004462.t001
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were analyzed by GraphPad Prism 4.03 program (GraphPad
Software).
Supporting Information
Figure S1 IL-37 reduces inflammation when adminis-
tered after the infection. C57BL/6 mice were infected
intranasally with A. fumigatus and treated with 1000 ng/mouse
IL-37 administered intraperitoneally for 3 consecutive days
starting the day of the infection. Mice were assessed for: (A)
number of total (T) cells and polymorphonuclear neutrophils (P) in
the BAL. Values represent the mean6SD of three mice per group
and are representative of 2 independent experiments; (B) lung
histology (periodic acid-Schiff staining) and cell recruitment
(insets). Scale bars, 100 mm and 25 mm in the insets; (C)
myeloperoxidase (Mpo) and Cxcl2 mRNA expression by RT-
PCR on total lung cells. Assays were done a day after the last
treatment. *P,0.05,**P,0.01, treated vs untreated (None) mice.
Naı¨ve, uninfected and untreated mice.
(TIF)
Figure S2 The anti-inflammatory activity of IL-37 in not
dependent on IL-10. Il102/2 mice were infected intranasally
with A. fumigatus and treated with 1000 ng/mouse IL-37
administered intraperitoneally 1 h before the infection. Mice were
assessed for: (A) number of total (T) cells and polymorphonuclear
neutrophils (P) in the BAL. Values represent the mean6SD of
three mice per group and are representative of 3 independent
experiments; (B) lung histology (periodic acid-Schiff staining) and
cell recruitment (insets). Scale bars, 100 mm and 25 mm in the
insets. Assays were done a day after the infection. *P,0.05, treated
vs untreated (None) mice. Naı¨ve, uninfected and untreated mice.
(TIF)
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